XML 26 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2024
Feb. 07, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Title of 12(b) Security Common Shares, nominal value CHF 0.03    
Trading Symbol CRSP    
Security Exchange Name NASDAQ    
Entity Registrant Name CRISPR THERAPEUTICS AG    
Entity Central Index Key 0001674416    
Entity Tax Identification Number 00-0000000    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   85,774,474  
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity File Number 001-37923    
Entity Address, Address Line One Baarerstrasse 14    
Entity Address, City or Town Zug    
Entity Address, Country CH    
Entity Address, Postal Zip Code 6300    
City Area Code 41 (0)41    
Local Phone Number 561 32 77    
Entity Interactive Data Current Yes    
Entity Incorporation, State or Country Code V8    
Document Annual Report true    
Document Transition Report false    
Entity Public Float     $ 4.3
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction Flag false    
Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement relating to the 2025 Annual General Meeting of Shareholders, which the Registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the Registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Report.

    
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location Boston, Massachusetts    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of CRISPR Therapeutics AG (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 11, 2025 expressed an unqualified opinion thereon.